- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04288921
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites (INSPIRE)
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Study Overview
Status
Intervention / Treatment
Detailed Description
The LumiraDx Influenza A/B + RSV Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx instrument for the qualitative detection and differentiation of Influenza type A, Influenza type B and respiratory syncytial virus (RSV) viral antigens. The test is not intended to detect influenza C antigens. The LumiraDx Influenza A/B + RSV assay uses nasal swabs or nasopharyngeal swab specimens, collected from symptomatic patients.
Approximately 2000 subjects will be enrolled in this study. 120 influenza A positive, 120 influenza B positive and 120 RSV positive samples are required, in addition to at least 120 samples negative for influenza and 120 negative RSV samples, representing four (4) age groups: ≤ 5 years, 6 to 21 years, 22 to 59 years, and ≥ 60 years. Depending on the prevalence of influenza A, influenza B or RSV, it will be necessary to collect a significantly higher number of total samples to obtain the required number of positives. Banked specimens may be used to supplement the data set.
The objectives of this clinical study are twofold:
- Evaluate the performance of the LumiraDx Influenza A/B + RSV Test in detecting and differentiating influenza A, influenza B and RSV in fresh nasal or nasopharyngeal swab specimens from patients with signs and symptoms of influenza and or RSV-like illness, as compared with an FDA-cleared comparative method.
- Evaluate LumiraDx Influenza A/B + RSV Test performance when the test is run by non-laboratory users in point-of-care (POC) locations representative of sites who perform testing under a CLIA certificate of waiver.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35235
- Recruiting
- MedHelp Urgent Care
-
-
California
-
Encinitas, California, United States, 92024
- Recruiting
- Access Medical Center
-
Madera, California, United States, 93637
- Recruiting
- Madera Family Medical Group
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Recruiting
- ImmunoE Health and Research
-
Northglenn, Colorado, United States, 80234
- Recruiting
- Complete Family Care Research
-
Thornton, Colorado, United States, 80233
- Recruiting
- ImmunoE Health and Research Center
-
-
Florida
-
DeLand, Florida, United States, 32720
- Recruiting
- Accel-West Volusia Pediatrics
-
Orlando, Florida, United States, 32829
- Recruiting
- Nona Pediatric Center
-
-
Kansas
-
Wichita, Kansas, United States, 67205
- Recruiting
- New Medical
-
-
Maryland
-
Millersville, Maryland, United States, 21108
- Recruiting
- Gvozden Pediatrics
-
-
New Jersey
-
Jackson, New Jersey, United States, 08527
- Recruiting
- Kent Plaza Pediatrics
-
Neptune, New Jersey, United States, 07753
- Recruiting
- Jersey Shore UMC
-
-
New Mexico
-
Santa Fe, New Mexico, United States, 87505
- Recruiting
- Southwest Care
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Recruiting
- Ardmore Family Practice
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
- Recruiting
- Lisa Connery MD
-
-
Texas
-
Carrollton, Texas, United States, 75010
- Recruiting
- Family Medical Associates
-
Plano, Texas, United States, 75093
- Recruiting
- North Texas Family Practice
-
-
Utah
-
Bountiful, Utah, United States, 84010
- Recruiting
- Pediatric Care
-
-
Virginia
-
Charlottesville, Virginia, United States, 22902
- Recruiting
- Pediatric Associates of Charlottesville
-
Vienna, Virginia, United States, 22180
- Recruiting
- Advanced Pediatrics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject may be of any age and either sex.
- Preliminary assessment of the subject by the Investigator/designee should be suggestive of influenza and/or RSV at the time of the study visit. The subject must exhibit two (2) or more of the following signs and symptoms for eligibility: stuffy or runny nose, sneezing, cough, sore throat, dyspnea (labored, difficult breathing), wheezing, fatigue, weakness and/or malaise, arthralgia (joint pain), myalgia (deep muscle aches), anorexia, vomiting, diarrhea, or headache. The onset of these symptoms must not have begun more than four (4) days prior to study enrollment.
- The subject must have a fever of 100.0 °F or greater with the onset of the fever being within the past three (3) days and/or present at the time of the visit. Fever can be reported or taken at time of visit. Subjects 18 years and older must report having a fever, but a quantitative reported measurement is not necessary for inclusion.
Exclusion Criteria:
- The subject underwent a nasal wash/aspirate as part of standard of care testing during this study visit.
- The subject is undergoing treatment currently and/or within the past 14 days of the study visit with an inhaled influenza vaccine (FluMist®) or anti-viral medication, which may include but is not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), or Baloxavir Marboxil (Xofluza™).
- The subject is undergoing treatment currently or had undergone within the past 14 days of the study visit with RSV-related medication which may include but is not limited to Ribavirin (Virazole), RSV-IGIV (RespiGam) or palivizumab (Synagis).
- The subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug, or device including either treatment or therapy.
- The subject has previously participated in this research study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nasal swab
Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
|
Swab samples for diagnostic test
|
Experimental: Nasopharyngeal swab
Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
|
Swab samples for diagnostic test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance evaluation by health care professionals
Time Frame: 4 months
|
Evaluate the performance of the LumiraDx Influenza A/B + RSV Test in detecting and differentiating influenza A, influenza B and RSV in fresh nasal or nasopharyngeal swab specimens from patients with signs and symptoms of influenza and or RSV-like illness, as compared with an FDA-cleared comparative method.
|
4 months
|
Performance evaluation by non-laboratory users
Time Frame: 4 months
|
Evaluate LumiraDx Influenza A/B + RSV Test performance when the test is run by non-laboratory users in point-of-care (POC) locations representative of sites who perform testing under a CLIA certificate of waiver.
|
4 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-CLIN-PROT-00015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza, Human
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
AVIR Green Hills Biotechnology AGCompletedSeasonal Human InfluenzaAustria
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Research Institute for Biological Safety ProblemsResearch Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...Completed
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Emergent BioSolutionsCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
Clinical Trials on Swab
-
LumiraDx UK LimitedActive, not recruiting
-
LumiraDx UK LimitedActive, not recruitingCOVID-19United States
-
University of VirginiaCompleted
-
Institut National de la Santé Et de la Recherche...CompletedInsufficient Intestinal Microbiota Diversity After C-section BirthFrance
-
Cairo UniversityCompletedFirst Trimester AbortionEgypt
-
Taher Abu HejlehHolden Comprehensive Cancer Center; Iowa Institute of Human GeneticsCompleted
-
Butantan InstituteCompleted
-
Public Health EnglandCompletedNasal Carriage of PneumococciUnited Kingdom
-
Rigshospitalet, DenmarkRecruitingCOVID-19 | Influenza | RSV InfectionDenmark